Cereta Andressa Daronco, Oliveira Vinícius Rosa, Costa Ivan Peres, Afonso João Pedro Ribeiro, Fonseca Adriano Luís, de Souza Alan Robson Trigueiro, Silva Guilherme Augusto Moreira, Mello Diego A C P G, de Oliveira Luis Vicente Franco, da Palma Renata Kelly
Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of São Paulo, São Paulo, Brazil.
Department of Physical Therapy, EUSES University School, University of Barcelona/University of Girona (UB-UdG), Barcelona, Spain.
Front Pharmacol. 2021 Apr 20;12:648506. doi: 10.3389/fphar.2021.648506. eCollection 2021.
Asthma is a widespread disease characterized by chronic airway inflammation. It causes substantial disability, impaired quality of life, and avoidable deaths around the world. The main treatment for asthmatic patients is the administration of corticosteroids, which improves the quality of life; however, prolonged use of corticosteroids interferes with extracellular matrix elements. Therefore, cell-based therapies are emerging as a novel therapeutic contribution to tissue regeneration for lung diseases. This study aimed to summarize the advancements in cell therapy involving mesenchymal stromal cells, extracellular vesicles, and immune cells such as T-cells in asthma. Our findings provide evidence that the use of mesenchymal stem cells, their derivatives, and immune cells such as T-cells are an initial milestone to understand how emergent cell-based therapies are effective to face the challenges in the development, progression, and management of asthma, thus improving the quality of life.
哮喘是一种以慢性气道炎症为特征的广泛存在的疾病。它在全球范围内导致了严重的残疾、生活质量受损以及可避免的死亡。哮喘患者的主要治疗方法是使用皮质类固醇，这可改善生活质量；然而，长期使用皮质类固醇会干扰细胞外基质成分。因此，基于细胞的疗法正在成为肺部疾病组织再生的一种新型治疗手段。本研究旨在总结涉及间充质基质细胞、细胞外囊泡以及免疫细胞（如T细胞）治疗哮喘的进展。我们的研究结果表明，使用间充质干细胞、其衍生物以及免疫细胞（如T细胞）是理解新兴的基于细胞的疗法如何有效应对哮喘发生、发展和管理中的挑战从而改善生活质量的一个初步里程碑。
